EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)

Jieun Lee

Journal of Clinical Medicine · 15.02.2023 · 12 (4) · 1524

DOI: 10.3390/jcm12041524 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.02.2023. Verfasst von Jieun Lee. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seou…. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT), Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea, Research Fund of Seoul St. Mary’s Hospital, The Catholic University of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy. Although novel agents are constantly being introduced for the treatment of breast cancer, conventional cytotoxic chemotherapy based on anthracyclines and taxanes is the mainstay treatment option for TNBC. Based on CTNeoBC pooled analysis data, the achievement of pathologic CR (pCR) in TNBC is directly linked to improved survival outcomes. Therefore, the treatment paradigm for early TNBC has shifted to neoadjuvant treatment, and the escalation of neoadjuvant chemotherapy to improve the pCR rate and the addition of post-neoadjuvant chemotherapy to control the residual disease have been investigated. In this article, we review the current treatment landscape for early TNBC, from standard cytotoxic chemotherapy to recent data on immune checkpoint inhibitors, capecitabine, and olaparib.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorneoadjuvant chemotherapytriple-negative breast cancer

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Cancer Research Institute, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Förderung

  • National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
  • Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea
  • Research Fund of Seoul St. Mary’s Hospital, The Catholic University of Korea

Zitieren

APA

Lee, J. (2023). Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). Journal of Clinical Medicine, 12(4), 1524. https://doi.org/10.3390/jcm12041524

Vancouver

Lee J. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). Journal of Clinical Medicine. 2023;12(4):1524. doi:10.3390/jcm12041524

BibTeX
@article{Lee2023,
  author = {Lee, Jieun},
  title = {Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {1524},
  doi = {10.3390/jcm12041524}
}
Kostenlos starten →